Edgemont Pharmaceuticals (EMED)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Pediatric CNSsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Short Interest
Short interest: 0.01% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- SEC 8-K 8-K/A [Amend] - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Anti-NMDA receptor encephalitis outcomes in a population-based cohort. — J Neurol 2026 Jul 15 PMID 42458126
- Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting. — Transl Psychiatry 2023 Dec 14 PMID 38097546
- Reward Behavior Disengagement, a Neuroeconomic Model-Based Objective Measure of Reward Pathology in Depression: Findings from the EMBARC Trial. — Behav Sci (Basel) 2023 Jul 25 PMID 37622759
- Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo. — Transl Psychiatry 2023 Apr 29 PMID 37120641
- Brain Ventricle and Choroid Plexus Morphology as Predictor of Treatment Response: Findings from the EMBARC Study. — Res Sq 2023 Mar 1 PMID 36909585
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Edgemont Pharmaceuticals.
Full EMED Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.